Immunization of knock-out α/β interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine

PLoS Neglected Tropical Diseases
Nurettin CanakoğluAykut Ozdarendeli

Abstract

Crimean-Congo hemorrhagic fever (CCHF) is an acute tick-borne zoonotic disease. The disease has been reported in many countries of Africa, Asia, the Middle East, and in Eurasia. During the past decade, new foci of CCHF have emerged in the Balkan Peninsula, southwest Russia, the Middle East, western China, India, Africa, and Turkey. CCHF virus produces severe hemorrhagic manifestations in humans with fatality rates up to 30%. Vaccine development efforts have been significantly hampered by a lack of animal models and therefore, no protective vaccine has been achieved. Lately, IFN α/β receptor deficient (IFNAR-/-) mice have been established as a novel small animal model of CCHF virus infection. In the present study, we found that IFNAR-/- mice highly susceptible to CCHF virus Turkey-Kelkit06 strain. Immunization with the cell culture based vaccine elicited a significant level of protection against high dose challenge (1,000 PPFU) with a homologous CCHF virus in IFNAR-/- mice.

References

Nov 20, 2004·Antiviral Research·Chris A Whitehouse
Apr 29, 2005·Journal of Virology·Andrea Bertolotti-CiarletRobert W Doms
Mar 24, 2006·The Lancet Infectious Diseases·Onder Ergönül
May 17, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·O ErgonulB Dokuzoguz
Jan 26, 2008·Emerging Infectious Diseases·Darja DuhTatjana Avsic-Zupanc
Nov 28, 2009·Virus Research·Aykut OzdarendeliAhmet Kalkan
Dec 17, 2009·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·S ChinikarA Haeri
Feb 19, 2010·The Journal of General Virology·Sándor BereczkyAli Mirazimi
May 21, 2010·Clinical and Vaccine Immunology : CVI·Ana SaksidaTatjana Avsic-Zupanc
Dec 15, 2010·Scandinavian Journal of Infectious Diseases·Anna PapaIva Christova
Mar 3, 2011·Antiviral Research·Maryam Keshtkar-JahromiSina Bavari
Apr 4, 2012·Emerging Infectious Diseases·Hürrem BodurYavuz Uyar
Aug 22, 2012·Journal of Virological Methods·Engin BerberAykut Ozdarendeli

❮ Previous
Next ❯

Citations

Apr 26, 2016·Viruses·Marko ZivcecÉric Bergeron
Sep 19, 2017·PLoS Neglected Tropical Diseases·Aura R GarrisonConnie S Schmaljohn
Nov 13, 2018·F1000Research·David W Hawman, Heinz Feldmann
Jul 3, 2019·Viruses·Aura R GarrisonJoseph W Golden
Mar 23, 2019·BMJ Global Health·Laura T Mazzola, Cassandra Kelly-Cirino
May 28, 2019·Scientific Reports·Sergio E RodriguezThomas W Geisbert
May 29, 2020·BioResearch Open Access·Thomas Tipih, Felicity Jane Burt
Jan 11, 2019·Viruses·Alejandro Marín-LopezJavier Ortego
Sep 20, 2020·Antiviral Research·Koray ErgünayAykut Özkul

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis
enzyme-linked immunosorbent assay
ELISA

Software Mentioned

GraphPad
GraphPad Prism

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Babesiosis

Babesiosis is caused by parasites of the genus babesia, which are transmitted in nature by the bite of an infected tick. Discover the latest research on babesiosis here.

Argentine Hemorrhagic Fever

Argentine hemorrhagic fever (AHF) is an endemo-epidemic disease caused by junín virus (JUNV), a member of the arenaviridae family. Discover the latest research on AHF here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.